Dupilumab and Prurigo Nodularis-like phenotype in Atopic Dermatitis: our experience of efficacy.

Dupilumab and Prurigo Nodularis-like phenotype in Atopic Dermatitis: our experience of efficacy. J Dermatolog Treat. 2019 Aug 23;:1-8 Authors: Ferrucci S, Tavecchio S, Berti E, Angileri L Abstract Atopic dermatitis (AD) is a common chronic multifactorial dermatosis that can occurs through different clinical phenotypes although all undergone identical pathogenetic mechanisms such as the Prurigo Nodularis (PN)-like phenotype. Here, we described eleven patients with PN-like atopic dermatitis treated with dupilumab, a human monoclonal IgG4 antibody that inhibits interleukine-4 (IL-4) and interleukine-13 (IL-13). Efficacy outcomes were performed at baseline, at first and fourth months from starting treatment. We collected different scores such as NRSi as well as IGA. At the same time, patient subjective benefits were analysed throught DLQI, POEM, HADS scores. Quality of sleep was also recorded by NRSS. All patients showed rapid clinical improvement of cutaneous lesions and no other new lesions were reported during treatment. Reduction of daily itching was referred already after the first month of treatment. These results shows the effectiviness of dupilumab in this clinical setting of AD, supporting this treatment as a valid therapeutic approch in difficult-to-treat-PN-like clinical presentation of AD. PMID: 31442084 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research